INT J LAB HEMATOL:淋巴细胞亚群在急性髓系白血病(AML)临床病理中的意义

2017-04-15 MedSci MedSci原创

虽然对免疫系统在改变和调节实体瘤进展中的作用有了很好的研究,但是免疫系统对血液淋巴瘤的发生和发展的作用仍然了解甚微。在本研究中,该团队报告了一项回顾性研究,详细介绍了对130例急性骨髓性白血病(AML)患者的分析,其中包括B细胞,T细胞和NK细胞在内的主要淋巴细胞亚群的流式细胞术免疫表型评估。

近日,国际杂志INT J LAB HEMATOL上在线发表一篇研究人员关于淋巴细胞亚群在急性髓系白血病(AML)临床病理中的意义的研究。

虽然对免疫系统在改变和调节实体瘤进展中的作用有了很好的研究,但是免疫系统对血液淋巴瘤的发生和发展的作用仍然了解甚微。

在本研究中,该团队报告了一项回顾性研究,详细介绍了对130例急性骨髓性白血病(AML)患者的分析,其中包括B细胞,T细胞和NK细胞在内的主要淋巴细胞亚群的流式细胞术免疫表型评估。

研究确定了与AML不同亚型有关的淋巴细胞亚群的差异特征,以及患者的预后相关性。在多变量分析中,发现NK细胞(特别是≥5%的截止值的CD56 + / CD16 + NK细胞)是整体改善和无病生存的独立指标。细胞遗传学风险对AML患者分层也是至关重要。

研究表明在AML中,免疫系统淋巴细胞的亚群分布是非随机的,并且表明不同淋巴细胞亚群,特别是NK细胞在该疾病中的重要作用。

原始出处:

M. Alcasid, L. Ma, J. R. Gotlib, D. et.al  The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia (pages 129–136) Version of Record online: 30 JAN 2017 | DOI: 10.1111/ijlh.12594

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1822039, encodeId=11f71822039cd, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Oct 01 04:00:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797461, encodeId=7b4b1e97461f6, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 25 17:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193909, encodeId=e6d31939090f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 05 05:58:51 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302054, encodeId=8dee1302054b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317271, encodeId=ae42131e2716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1822039, encodeId=11f71822039cd, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Oct 01 04:00:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797461, encodeId=7b4b1e97461f6, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 25 17:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193909, encodeId=e6d31939090f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 05 05:58:51 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302054, encodeId=8dee1302054b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317271, encodeId=ae42131e2716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1822039, encodeId=11f71822039cd, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Oct 01 04:00:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797461, encodeId=7b4b1e97461f6, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 25 17:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193909, encodeId=e6d31939090f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 05 05:58:51 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302054, encodeId=8dee1302054b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317271, encodeId=ae42131e2716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-05-05 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1822039, encodeId=11f71822039cd, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Oct 01 04:00:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797461, encodeId=7b4b1e97461f6, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 25 17:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193909, encodeId=e6d31939090f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 05 05:58:51 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302054, encodeId=8dee1302054b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317271, encodeId=ae42131e2716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1822039, encodeId=11f71822039cd, content=<a href='/topic/show?id=ee4b1021266e' target=_blank style='color:#2F92EE;'>#髓系白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102126, encryptionId=ee4b1021266e, topicName=髓系白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Oct 01 04:00:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797461, encodeId=7b4b1e97461f6, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 25 17:00:00 CST 2017, time=2017-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=193909, encodeId=e6d31939090f, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri May 05 05:58:51 CST 2017, time=2017-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302054, encodeId=8dee1302054b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317271, encodeId=ae42131e2716e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 15:00:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-04-16 fengyi812

相关资讯

Lancet Haematol:HSCT治疗60岁及以上急性髓系白血病患者缓解后的治疗

急性髓细胞白血病主要影响老年人,并且在中位年龄为70岁左右时被诊断。尽管约50-60%的患者在进入密集的诱导化疗后可以完全缓解,但复发率仍然很高,总的结果是令人失望的。因此,有效的缓解后治疗是迫切需要的。虽然通常没有缓解后疗法给予老年患者,它可能包括化疗或同种异体造血干细胞移植(HSCT)之后降低强度调节。该研究的目的是评估比较异体移植与其他方法,包括无缓解后治疗,对于年龄在60岁以上急性髓性白血

2016NCCN临床实践指南:急性髓系白血病(Version2.2016)

2016年7月,美国国家综合癌症网络(NCCN)发布了急性髓系白血病指南2016年第2版,指南更新摘要。

科学家在急性髓系白血病的诱导分化疗法研究中取得进展

急性髓系白血病(acute myeloid leukemia, AML)是一种高度异质性的血液系统恶性肿瘤。AML的传统治疗主要采用大剂量联合化疗,但此疗法副作用大、复发率高。急性早幼粒细胞白血病(APL)是AML的一种亚型,与大多数AML化疗预后不良相比,针对APL的全反式维甲酸(ATRA)诱导分化疗法预后良好,这一结果提示诱导分化疗法有望应用于AML的治疗。